🇺🇸 FDA
Patent

US 9593082

Compositions and methods for inhibition of the JAK pathway

granted A61KA61K31/505A61P

Quick answer

US patent 9593082 (Compositions and methods for inhibition of the JAK pathway) held by Rigel Pharmaceuticals, Inc. expires Mon Mar 09 2037 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Rigel Pharmaceuticals, Inc.
Grant date
Tue Mar 14 2017 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Mar 09 2037 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
17
CPC classes
A61K, A61K31/505, A61P, A61P35/00, A61P35/02